

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
July 01, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

July 1, 2009

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b):82-\_\_\_\_\_

TREASURY STOCK

STATUS REGARDING NOVO NORDISK'S HOLDING OF ITS OWN SHARES (30 JUNE 2009)

In continuation of the company's announcement dated 29 January 2009 concerning a  
planned share repurchase programme, and pursuant to Section 204.25 of the New  
York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk  
A/S (NYSE: NVO) and its wholly-owned affiliates on 30 June 2009 owned 19,326,741

## Edgar Filing: NOVO NORDISK A S - Form 6-K

of its own B shares of DKK 1, corresponding to a total nominal value of DKK 19,326,741 or 3.12% of the total share capital.

In the second quarter of 2009 a total of 4,992,182 B shares were repurchased, and 60,323 B shares were disposed of to employees in connection with employee incentive programmes.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

For further information please contact:

Media:

Investors:

Outside North America:

Elin K Hansen

Tel: (+45) 4442 3450

[ekh@novonordisk.com](mailto:ekh@novonordisk.com)

Outside North America:

Mads Veggerby Lausten

Tel: (+45) 4443 7919

[mlau@novonordisk.com](mailto:mlau@novonordisk.com)

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471

[krop@novonordisk.com](mailto:krop@novonordisk.com)

In North America:

Sean Clements

Tel: (+1) 609 514 8316

[secl@novonordisk.com](mailto:secl@novonordisk.com)

In North America:

Hans Rommer

Tel: (+1) 609 919 7937

[hrrmm@novonordisk.com](mailto:hrrmm@novonordisk.com)

Company Announcement no 38 2009

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: July 1, 2009

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer